Now showing items 1-19 of 19

    • Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. 

      Rini, BI; Dorff, TB; Elson, P; Rodriguez, CS; Shepard, D; Wood, L; Humbert, J; Pyle, L; Wong, Y-N; Finke, JH; Rayman, PA; Larkin, JMG; Garcia, JA; Plimack, ER (2016-09)
      <h4>Background</h4>A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases. Because of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit ...
    • Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. 

      Stewart, GD; Aitchison, M; Bex, A; Larkin, J; Lawless, C; Méjean, A; Nathan, P; Oades, G; Patard, J-J; Paul, J; Ravaud, A; Escudier, B; Renal Cross Channel Group (2017-06)
      Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting ...
    • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-12)
      The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
    • Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. 

      Fisher, R; Horswell, S; Rowan, A; Salm, MP; de Bruin, EC; Gulati, S; McGranahan, N; Stares, M; Gerlinger, M; Varela, I; Crockford, A; Favero, F; Quidville, V; André, F; Navas, C; Grönroos, E; Nicol, D; Hazell, S; Hrouda, D; O'Brien, T; Matthews, N; Phillimore, B; Begum, S; Rabinowitz, A; Biggs, J; Bates, PA; McDonald, NQ; Stamp, G; Spencer-Dene, B; Hsieh, JJ; Xu, J; Pickering, L; Gore, M; Larkin, J; Swanton, C (2014-08-27)
      <h4>Background</h4>Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.<h4>Results</h4>We perform whole exome sequencing ...
    • Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. 

      Gravis, G; Chanez, B; Derosa, L; Beuselinck, B; Barthelemy, P; Laguerre, B; Brachet, P-E; Joly, F; Escudier, B; Harrison, DJ; Laird, A; Vasudev, N; Ralph, C; Larkin, J; Lote, H; Salem, N; Walz, J; Thomassin, J; Sfumato, P; Stewart, GD; Boher, JM; Renal Cross Channel Group (2016-04)
      <h4>Background</h4>Glandular metastases (GMs) (pancreas, breast, parotid, thyroid, or contralateral adrenal) are rare in metastatic clear cell renal cell carcinoma (mccRCC). In a multicenter study we have assessed outcome ...
    • Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. 

      Machiela, MJ; Hofmann, JN; Carreras-Torres, R; Brown, KM; Johansson, M; Wang, Z; Foll, M; Li, P; Rothman, N; Savage, SA; Gaborieau, V; McKay, JD; Ye, Y; Henrion, M; Bruinsma, F; Jordan, S; Severi, G; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Mannisto, S; Weinstein, S; Clark, PE; Edwards, TE; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Gaziano, JM; Sesso, HS; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Colli, LM; Sampson, JN; Besse, C; Blanche, H; Boland, A; Burdette, L; Prokhortchouk, E; Skryabin, KG; Yeager, M; Mijuskovic, M; Ognjanovic, M; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Bueno-de-Mesquita, HB; Canzian, F; Duell, EJ; Ljungberg, B; Sitaram, RT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Larkin, J; Choueiri, TK; Lathrop, GM; Teh, BT; Deleuze, J-F; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ; Scelo, G; Purdue, MP (2017-11)
      <h4>Background</h4>Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings.<h4>Objective</h4>We ...
    • Genome-wide association study identifies multiple risk loci for renal cell carcinoma. 

      Scelo, G; Purdue, MP; Brown, KM; Johansson, M; Wang, Z; Eckel-Passow, JE; Ye, Y; Hofmann, JN; Choi, J; Foll, M; Gaborieau, V; Machiela, MJ; Colli, LM; Li, P; Sampson, JN; Abedi-Ardekani, B; Besse, C; Blanche, H; Boland, A; Burdette, L; Chabrier, A; Durand, G; Le Calvez-Kelm, F; Prokhortchouk, E; Robinot, N; Skryabin, KG; Wozniak, MB; Yeager, M; Basta-Jovanovic, G; Dzamic, Z; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Baglietto, L; Boeing, H; Khaw, K-T; Weiderpass, E; Ljungberg, B; Sitaram, RT; Bruinsma, F; Jordan, SJ; Severi, G; Winship, I; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Männistö, S; Weinstein, S; Clark, PE; Edwards, TL; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Michael Gaziano, J; Sesso, HD; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Teh, BT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Henrion, M; Larkin, J; Barman, P; Leibovich, BC; Choueiri, TK; Mark Lathrop, G; Rothman, N; Deleuze, J-F; McKay, JD; Parker, AS; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ (2017-06-09)
      Previous genome-wide association studies (GWAS) have identified six risk loci for renal cell carcinoma (RCC). We conducted a meta-analysis of two new scans of 5,198 cases and 7,331 controls together with four existing ...
    • How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. 

      Bracarda, S; Negrier, S; Casper, J; Porta, C; Schmidinger, M; Larkin, J; Gross Goupil, M; Escudier, B (2017-03)
      <h4>Introduction</h4>Currently, sunitinib is a standard of care in first-line treatment for metastatic renal cell carcinoma (mRCC). However, with the standard 4/2 schedule (sunitinib 50 mg/day; 4 consecutive weeks on ...
    • The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. 

      Johansson, M; Carreras-Torres, R; Scelo, G; Purdue, MP; Mariosa, D; Muller, DC; Timpson, NJ; Haycock, PC; Brown, KM; Wang, Z; Ye, Y; Hofmann, JN; Foll, M; Gaborieau, V; Machiela, MJ; Colli, LM; Li, P; Garnier, J-G; Blanche, H; Boland, A; Burdette, L; Prokhortchouk, E; Skryabin, KG; Yeager, M; Radojevic-Skodric, S; Ognjanovic, S; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Weiderpass, E; Ljungberg, B; Tumkur Sitaram, R; Häggström, C; Bruinsma, F; Jordan, SJ; Severi, G; Winship, I; Hveem, K; Vatten, LJ; Fletcher, T; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Andreotti, G; Beane Freeman, LE; Koutros, S; Männistö, S; Weinstein, S; Clark, PE; Edwards, TL; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Wilson, KM; Gaziano, JM; Sesso, HD; Freedman, ND; Parker, AS; Eckel-Passow, JE; Huang, W-Y; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Teh, BT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Eisen, T; Henrion, M; Larkin, J; Barman, P; Leibovich, BC; Choueiri, TK; Lathrop, GM; Deleuze, J-F; Gunter, M; McKay, JD; Wu, X; Houlston, RS; Chanock, SJ; Relton, C; Richards, JB; Martin, RM; Davey Smith, G; Brennan, P (2019-01-03)
      <h4>Background</h4>Several obesity-related factors have been associated with renal cell carcinoma (RCC), but it is unclear which individual factors directly influence risk. We addressed this question using genetic markers ...
    • Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. 

      Turajlic, S; Litchfield, K; Xu, H; Rosenthal, R; McGranahan, N; Reading, JL; Wong, YNS; Rowan, A; Kanu, N; Al Bakir, M; Chambers, T; Salgado, R; Savas, P; Loi, S; Birkbak, NJ; Sansregret, L; Gore, M; Larkin, J; Quezada, SA; Swanton, C (2017-08)
      <h4>Background</h4>The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated ...
    • Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. 

      O'Reilly, A; Larkin, J (2017-03)
      <h4>Introduction</h4>In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number ...
    • Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. 

      Colomba, E; Le Teuff, G; Eisen, T; Stewart, GD; Fife, K; Larkin, J; Biondo, A; Pickering, L; Srinivasan, A; Boyle, H; Derosa, L; Sternberg, CN; Recine, F; Ralph, C; Saldana, C; Barthélémy, P; Bernhard, JC; Gurney, H; Verhoest, G; Vauleon, E; Bigot, P; Berger, J; Pfister, C; Gravis, G; Rodier, J-M; Culine, S; Caty, A; Rolland, F; Priou, F; Escudier, B; Albiges, L (2017-07)
      <h4>Background</h4>Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and ...
    • Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. 

      Bridgeman, VL; Wan, E; Foo, S; Nathan, MR; Welti, JC; Frentzas, S; Vermeulen, PB; Preece, N; Springer, CJ; Powles, T; Nathan, PD; Larkin, J; Gore, M; Vasudev, NS; Reynolds, AR (2016-01)
      Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this ...
    • Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. 

      Grande, E; Glen, H; Aller, J; Argenziano, G; Lamas, MJ; Ruszniewski, P; Zamorano, JL; Edmonds, K; Sarker, S; Staehler, M; Larkin, J (2017-12)
      <h4>Introduction</h4>There are several second-line treatment options for patients with renal cell carcinoma after first-line failure of a tyrosine kinase inhibitor, especially with the recent approvals of cabozantinib, ...
    • Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. 

      Rothermundt, C; von Rappard, J; Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Rini, B; Schmidinger, M; Sternberg, CN; Putora, PM (2017-04)
      <h4>Background</h4>Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for ...
    • Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. 

      Gulati, S; Martinez, P; Joshi, T; Birkbak, NJ; Santos, CR; Rowan, AJ; Pickering, L; Gore, M; Larkin, J; Szallasi, Z; Bates, PA; Swanton, C; Gerlinger, M (2014-11)
      <h4>Background</h4>Candidate biomarkers have been identified for clear cell renal cell carcinoma (ccRCC) patients, but most have not been validated.<h4>Objective</h4>To validate published ccRCC prognostic biomarkers in an ...
    • Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Chambers, T; Lopez, JI; Nicol, D; O'Brien, T; Larkin, J; Horswell, S; Stares, M; Au, L; Jamal-Hanjani, M; Challacombe, B; Chandra, A; Hazell, S; Eichler-Jonsson, C; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Jabbar, F; Spain, L; Lall, S; Guarch, R; Falzon, M; Proctor, I; Pickering, L; Gore, M; Watkins, TBK; Ward, S; Stewart, A; DiNatale, R; Becerra, MF; Reznik, E; Hsieh, JJ; Richmond, TA; Mayhew, GF; Hill, SM; McNally, CD; Jones, C; Rosenbaum, H; Stanislaw, S; Burgess, DL; Alexander, NR; Swanton, C; PEACE; TRACERx Renal Consortium (2018-04-12)
      Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with ...
    • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. 

      Choueiri, TK; Motzer, RJ; Rini, BI; Haanen, J; Campbell, MT; Venugopal, B; Kollmannsberger, C; Gravis-Mescam, G; Uemura, M; Lee, JL; Grimm, M-O; Gurney, H; Schmidinger, M; Larkin, J; Atkins, MB; Pal, SK; Wang, J; Mariani, M; Krishnaswami, S; Cislo, P; Chudnovsky, A; Fowst, C; Huang, B; di Pietro, A; Albiges, L (2020-08)
      <h4>Background</h4>The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma ...